Optiver Holding
URGN icon

Optiver Holding’s UroGen Pharma URGN Stock Holding History

Optiver Holding’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.73K Sell
152
-71
-32% -$1.42K ﹤0.01% 1710
2025
Q4 		$5.22K Sell
223
-59
-21% -$1.28K ﹤0.01% 1334
2025
Q3 		$5.63K Buy
+282
New +$5.06K ﹤0.01% 1644

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Optiver Holding's URGN Position: Q1 2026 in Review

Optiver Holding reduced its UroGen Pharma (URGN) stake by 32% in Q1 2026, selling an estimated $1.42K and leaving 152 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1710.

Optiver Holding first reported a position in URGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.63K in Q3 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Optiver Holding held 152 shares of UroGen Pharma worth $2.73K as of Q1 2026.
  • Optiver Holding sold 71 UroGen Pharma shares in Q1 2026, an estimated $1.42K.
  • UroGen Pharma made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1710 holding.
  • Optiver Holding first reported a position in UroGen Pharma in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's UroGen Pharma position peaked at $5.63K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.